bluebird bio
A biotechnology company that developed lentiviral gene therapies for severe inherited diseases and cell therapies for cancer.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
History
bluebird bio was established in April 1992 as Genetix Pharmaceuticals by MIT faculty members Philippe Leboulch and Irving London. The company initially pursued genetic medicines for severe inherited blood disorders, particularly beta-thalassemia and sickle cell disease. Its leading approach used a lentiviral vector to add a functional gene to a patient's hematopoietic stem cells. The modified cells could then generate blood cells capable of producing a therapeutic form of hemoglobin. Walter Ogier served as chief executive officer from 2001 to 2005, during a period when the business was focused on advancing Lentiglobin. A significant clinical milestone came in 2010, when investigators at Hospital Necker in Paris reported prolonged transfusion independence in a patient with severe beta-thalassemia who had received the therapy. Published results described the finding as an important demonstration of long-term correction of a major inherited disease through gene therapy. In September 2010, Genetix Pharmaceuticals changed its name to bluebird bio, and Nick Leschly became chief executive officer. The renamed company pursued clinical development in blood disorders while broadening its work to other genetic diseases and cancer immunotherapy. It completed an initial public offering in June 2013 and acquired Precision Genome Engineering in June 2014 for consideration reported as potentially reaching $156 million. The oncology strategy included a 2017 collaboration with Celgene, now part of Bristol Myers Squibb, around bb2121, a BCMA-directed CAR-T therapy. The program later became associated with idecabtagene vicleucel. In 2020, the FDA first issued a refusal-to-file letter concerning the marketing application and later accepted a revised application. bluebird bio also announced a 2018 collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialize new cell therapies for cancer. The company achieved its first major regulatory milestones in inherited diseases with Zynteglo and Skysona. The European Commission authorized Zynteglo in 2019 for transfusion-dependent beta-thalassemia. The therapy received United States approval in 2022, with orphan-drug and breakthrough-therapy designations for the relevant indication. Skysona was authorized in the European Union in 2021 for cerebral adrenoleukodystrophy. In November 2021, bluebird bio completed the corporate separation of its oncology business into 2seventy bio. In December 2023, the FDA approved Lyfgenia, the commercial name for lovotibeglogene autotemcel, for specified patients with sickle cell disease. The treatment became part of a new commercial model involving specialist manufacturing and administration as well as extended follow-up. bluebird bio announced outcomes-based contracts under which payer obligations could be reduced if defined vaso-occlusive outcomes occurred during a monitoring period. The company also reported reimbursement agreements covering approximately 200 million people in the United States. Commercialization remained difficult because individualized gene therapies require complex infrastructure and can carry very high one-time prices. Zynteglo attracted criticism because of its reported $1.8 million price. Lyfgenia was announced with a wholesale acquisition cost of $3.1 million, and its label includes a boxed warning about the potential risk of hematologic malignancy. These issues contributed to broader debate about access, reimbursement, long-term safety, and how health systems should pay for durable gene-therapy benefits. bluebird bio undertook workforce reductions in 2022 and 2024, each reported as affecting approximately one-quarter to three-tenths of employees. The supplied reference material further states that investment funds managed by The Carlyle Group and SK Capital Partners acquired the company in June 2025 and that the business subsequently rebranded as Genetix Biotherapeutics. The available material does not clarify whether bluebird bio continued as a separate operating brand or legal entity after that transaction.
- 2025
Acquisition and reported rebranding
[1]Reference material states that Carlyle- and SK Capital-managed funds acquired the company and that it later became Genetix Biotherapeutics.
- 2023
United States approval of Lyfgenia
[1]The FDA approved lovotibeglogene autotemcel for eligible patients with sickle cell disease.
- 2022
United States approval of Zynteglo
[1]The FDA approved Zynteglo for transfusion-dependent beta-thalassemia.
- 2021
European authorization of Skysona
[1]The European Commission authorized elivaldogene autotemcel for cerebral adrenoleukodystrophy.
- 2021
2seventy bio spin-off
[1]bluebird bio completed the separation of its oncology-focused business into 2seventy bio.
- 2019
European authorization of Zynteglo
[1]The European Commission authorized betibeglogene autotemcel for transfusion-dependent beta-thalassemia.
- 2014
Precision Genome Engineering acquisition
[1]The company acquired Precision Genome Engineering in a transaction reported as worth up to $156 million.
- 2013
Initial public offering
[1]bluebird bio became a public company through an offering that raised $116 million.
- 2010
Company adopts the bluebird bio name
[1]Genetix Pharmaceuticals was renamed bluebird bio, with Nick Leschly appointed chief executive officer.
- 2010
Long-term beta-thalassemia result is reported
[1]Nature published results describing prolonged transfusion independence after Lentiglobin treatment in a patient with severe beta-thalassemia.
Products and positioning
Specialist developer and commercializer of high-complexity gene therapies for severe inherited diseases, with additional experience in engineered cellular immunotherapies.
Gene therapy · 2019
Zynteglo
Zynteglo is the brand name for betibeglogene autotemcel, an autologous lentiviral gene therapy for transfusion-dependent beta-thalassemia. A patient's blood-forming stem cells are collected, genetically modified to support production of functional beta-globin, and reinfused after conditioning treatment. It received European authorization in 2019 and United States FDA approval in 2022. Its high one-time price has made it a prominent example in discussions about gene-therapy affordability and reimbursement.
Gene therapy · 2021
Skysona
Skysona is the brand name for elivaldogene autotemcel, an autologous gene therapy developed for cerebral adrenoleukodystrophy, a severe inherited disorder that can damage the brain's white matter. The product uses a patient's own genetically modified hematopoietic stem cells. The European Commission authorized it in 2021. Its development expanded bluebird bio's lentiviral platform beyond inherited blood disorders.
Gene therapy · 2023
Lyfgenia
Lyfgenia is the commercial name for lovotibeglogene autotemcel, an autologous gene therapy for patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events. The FDA approved it in December 2023. The treatment is administered through a complex cell-collection and manufacturing process and requires long-term follow-up. Its United States label includes a boxed warning concerning the potential risk of hematologic malignancy.
Gene-therapy platform and product candidate
LentiGlobin
LentiGlobin was the company's principal lentiviral gene-therapy program during its early development history. It was studied for severe inherited blood disorders, including beta-thalassemia and sickle cell disease, and served as the foundation for later commercial products such as Zynteglo and Lyfgenia.
Controversies
Brand decisions
2025
Acquisition by investment funds and reported rebrandingM&ABackground
The company underwent restructuring and workforce reductions while commercializing high-cost individualized gene therapies.
Action taken
Reference material states that funds managed by The Carlyle Group and SK Capital Partners acquired the company and subsequently rebranded it as Genetix Biotherapeutics.
Aftermath
The continuing legal and operating status of the bluebird bio brand is not clear from the supplied references.
2023
Commercialize Lyfgenia with outcomes-based reimbursementProduct launchBackground
Lyfgenia's one-time treatment cost and complex administration created substantial reimbursement and affordability challenges.
Action taken
After FDA approval, bluebird bio introduced outcomes-based contracts with a monitoring period during which payer obligations could be reduced if specified sickle-cell-related hospitalizations occurred.
Aftermath
The company reported two reimbursement agreements covering approximately 200 million people in the United States.
Announced wholesale acquisition cost for Lyfgenia. $3.1 million (2023)
2021
Separate oncology operations into 2seventy bioStrategyBackground
The company had developed oncology cell-therapy programs alongside its inherited-disease gene-therapy portfolio.
Action taken
bluebird bio completed a corporate spin-off that created 2seventy bio as an oncology-focused company.
Aftermath
The transaction left bluebird bio more concentrated on gene therapies for inherited diseases.
2010
Rebrand as bluebird bioStrategyBackground
Genetix Pharmaceuticals was developing lentiviral therapies for severe inherited diseases and sought a broader identity for its growth and clinical-stage business.
Action taken
The company changed its name to bluebird bio and appointed Nick Leschly as chief executive officer.
Aftermath
The new identity preceded the company's public offering, expanded partnerships, and later commercialization of gene therapies.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/bluebird-bio · Editorial policy · How profiles are compiled